Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERGE phase 3 trial of claseprubart in generalized myasthenia gravis
2026-525298-38-00Phase 3Authorised
- Sponsor
- Dianthus Therapeutics
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Claseprubart with Placebo (2 arms). Primary endpoint: Change from baseline to Week 17 in MG-ADL scale score. Planned start Sep 2026; status: authorised.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2026-525298-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525298-38-00.